Gemzar

(gemcitabine hydrochloride)

Phase 3Small molecule

Gemcitabine is a chemotherapy drug used to treat various types of cancer, including pancreatic cancer, lung cancer, and breast cancer, by slowing or stopping the growth of cancer cells.[1] Gemzar is currently being investigated across 72 indications[3], with its most advanced program in Phase 3.[1]

Gemzar is one of 1143 small molecule programs targeting Urinary Bladder Carcinoma. It is currently in Phase 3.

Indications

478

Total Trials

Active Trials

1,142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Bladder CarcinomaActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

LeiomyosarcomaActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

T-Cell Non-Hodgkin LymphomaActive, not recruiting

Nasopharyngeal NeoplasmActive, not recruiting

Transitional Cell CarcinomaActive, not recruiting

LymphomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Urinary Bladder CarcinomaPhase 2

Active, not recruiting

Uterine LeiomyosarcomaPhase 3

Active, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

T-Cell Non-Hodgkin LymphomaPhase 2

Active, not recruiting

Nasopharyngeal NeoplasmPhase 1

Active, not recruiting

Transitional Cell CarcinomaPhase 3

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Showing 10 of 72 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Phase 3

22 2

Halaven

Eisai

Preclinical

38 3

Avastin

Lexiscan

1 5

Adenocard

Astellas

Preclinical

1 6

Voltaren

Novartis

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Acupan

YYonsei University

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Peritoneal Cancer

NCT01970722

Phase 2Active, not recruiting

Kidney Cancer

NCT03587662

Phase 1Active, not recruiting

Pancreatic Cancer

NCT00878163

Q3 2027

Phase 2Not yet recruiting

Gallbladder Cancer

NCT06591650

Q1 2028

Phase 3Active, not recruiting

Fallopian Tube Cancer

NCT00565851

Q1 2030

Phase 2Recruiting

Refractory Solid Tumors

NCT05733000

Clinical

Trials by Indication[1]

Pancreatic Cancer44 trials

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01013649·546 enrolled

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00114179·82 enrolled

Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT00303758·202 enrolled

Show 41 more trials

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00634725·820 enrolled

Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·MMayo Clinic·Phase 1·NCT01893294·1 enrolled

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00063947·28 enrolled

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Terminated·GGary Morrow·Phase 3·NCT00031837·400 enrolled

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00095966·35 enrolled

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Completed·MMohammed Najeeb Al Hallak·Phase 1/2·NCT02178436·15 enrolled

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00047307·46 enrolled

Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00268411·80 enrolled

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Completed·TTranslational Oncology Research International·Phase 2·NCT01234935·8 enrolled

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Completed·UUNICANCER·Phase 2/3·NCT00112658·342 enrolled

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Unknown status·IInstitut Paoli-Calmettes·Phase 3·NCT00541021·104 enrolled

Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer

Completed·IIRCCS San Raffaele·Phase 2/3·NCT00960284·102 enrolled

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01497392·26 enrolled

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT02562716·147 enrolled

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00878163·55 enrolled

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004190·59 enrolled

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003546·43 enrolled

Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer

Completed·TTechnical University of Munich·Phase 2·NCT00425841·29 enrolled

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Terminated·AAndrew Ko·Phase 2·NCT00429858·21 enrolled

Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer

Completed·RRoyal Liverpool University Hospital·Phase 3·NCT00058201·1,030 enrolled

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00039403·30 enrolled

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05685602·43 enrolled

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Completed·CCentre Antoine Lacassagne·Phase 1·NCT00885066·30 enrolled

Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·CCancer Research UK·Phase 3·NCT00032175·508 enrolled

Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00064207·97 enrolled

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·HHull University Teaching Hospitals NHS Trust·Phase 2·NCT00462852·120 enrolled

Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00114244·52 enrolled

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00376948·20 enrolled

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00462553·37 enrolled

Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer

Completed·IIRCCS San Raffaele·Phase 2·NCT00966706·105 enrolled

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Active, not recruiting·FFlemming Forsberg·Phase 1/2·NCT04821284·120 enrolled

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Terminated·—·Phase 2·NCT02383433·2 enrolled

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01660971·19 enrolled

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00078975·26 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00026403·48 enrolled

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00058149

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00617708·134 enrolled

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Unknown status·AAstex Pharmaceuticals, Inc.·Phase 3·NCT00005869

Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00275119

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Terminated·FFox Chase Cancer Center·Phase 1·NCT01739439·6 enrolled

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT00089024·29 enrolled

Non-Small Cell Lung Cancer30 trials

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·N/A·NCT02145078·4 enrolled

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01282333·44 enrolled

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Unknown status·TThe Christie NHS Foundation Trust·Phase 2/3·NCT00022009

Show 27 more trials

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00469976

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00041314

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003037

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00003159·600 enrolled

Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00004199

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 2·NCT00564733·55 enrolled

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00863512·34 enrolled

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075751·99 enrolled

Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00075517

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00103051

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT00062270

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Terminated·CCTI BioPharma·Phase 3·NCT00054197

Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 1/2·NCT00003202·40 enrolled

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT00004160·72 enrolled

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00343408·31 enrolled

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00057798·21 enrolled

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Completed·CCancer Therapeutics Research Group·Phase 2·NCT00077415·31 enrolled

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1·NCT00016315·35 enrolled

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01443078·42 enrolled

Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 3·NCT00074204·17 enrolled

A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077350·48 enrolled

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00022646·157 enrolled

Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00004201

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00970684·13 enrolled

Lymphoma14 trials

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed·BBeth Christian·Phase 1/2·NCT01535924·26 enrolled

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00060112·15 enrolled

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00337194·30 enrolled

Show 11 more trials

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00086801·104 enrolled

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

Withdrawn·UUniversity of Miami·Phase 2·NCT00881387

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00014209·77 enrolled

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00293345·30 enrolled

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01780662·46 enrolled

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Terminated·NNorthwestern University·Phase 1/2·NCT00290706·32 enrolled

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00019513·108 enrolled

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00920153·442 enrolled

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00574496·25 enrolled

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00079261·25 enrolled

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Completed·—·Phase 1/2·NCT00863369·33 enrolled

Breast Cancer13 trials

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00059852·61 enrolled

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00006459

Management of Metastatic Breast Cancer in Frail Patients

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005614

Show 10 more trials

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

Completed·JJoseph Baar, MD, PhD·Phase 1·NCT02479230·18 enrolled

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Terminated·UUniversity of Southampton·Phase 2·NCT00470249·5 enrolled

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled

Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003540·30 enrolled

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1·NCT02046421·31 enrolled

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Unknown status·NNSABP Foundation Inc·Phase 3·NCT00408408·1,206 enrolled

Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002998·59 enrolled

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated·MMayo Clinic·Phase 1·NCT03432741·17 enrolled

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006007·59 enrolled

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00100750·31 enrolled

Patients With Advanced Solid Tumors9 trials

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

Completed·UUniversity of Pittsburgh·Phase 1·NCT00008125·25 enrolled

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Completed·UUniversity of Nebraska·Phase 1·NCT00483366·13 enrolled

SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors

Unknown status·JJonsson Comprehensive Cancer Center·Phase 1·NCT00005996

Show 6 more trials

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Withdrawn·RRoswell Park Cancer Institute·Phase 1·NCT01971489

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00620295·17 enrolled

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00007917·58 enrolled

Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT01093092·14 enrolled

Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors

Completed·FFox Chase Cancer Center·Phase 1·NCT00021346·8 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006372·10 enrolled

52 more indications

Bladder Cancer8 trials

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Terminated·MMedical University of South Carolina·Phase 2·NCT00089128·16 enrolled

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

Completed·SSWOG Cancer Research Network·Phase 2·NCT00234039·58 enrolled

Combination Chemotherapy in Treating Patients With Bladder Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00014534·42 enrolled

Show 5 more trials

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Terminated·FFox Chase Cancer Center·Phase 2·NCT01611662·32 enrolled

Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Unknown status·FFondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy·Phase 3·NCT00054626·700 enrolled

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003105·30 enrolled

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Withdrawn·MMayo Clinic·N/A·NCT02944357

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00445601·406 enrolled

Kidney Cancer6 trials

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

Completed·—·Phase 2·NCT00003928·32 enrolled

Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

Completed·TThe Cleveland Clinic·Phase 2·NCT00401128·9 enrolled

Show 3 more trials

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00121251·17 enrolled

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03587662·30 enrolled

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00042965·60 enrolled

Advanced Cancer4 trials

Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer

Completed·—·Phase 1·NCT00004220

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00005644

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003707·22 enrolled

Show 1 more trial

SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00006351·34 enrolled

Cancer of the Pancreas4 trials

Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

Unknown status·—·Phase 2·NCT00003797·41 enrolled

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003216·518 enrolled

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003810

Show 1 more trial

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00012220·259 enrolled

Radiation Therapy3 trials

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00467116·9 enrolled

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00305877·137 enrolled

Biliary Tract Cancer3 trials

ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer

Completed·UUniversity of Nebraska·Phase 1·NCT01825603·17 enrolled

Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery

Completed·UUNICANCER·Phase 3·NCT01313377·190 enrolled

Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT00304135·34 enrolled

Metastatic Solid Tumors3 trials

Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079352·24 enrolled

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNorthwestern University·Phase 1·NCT00004095·38 enrolled

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00410553·45 enrolled

Fallopian Tube Cancer3 trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00565851·1,052 enrolled

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Unknown status·MMedical University Innsbruck·Phase 2·NCT01100372·154 enrolled

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003382

Colorectal Cancer2 trials

Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan

Unknown status·YYonsei University·Phase 1/2·NCT00496704·56 enrolled

Gemcitabine in Treating Patients With Advanced Colorectal Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00007943·15 enrolled

Urothelial Cancer2 trials

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Completed·UUniversity of California, Davis·Phase 1·NCT02437370·32 enrolled

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Terminated·MMayo Clinic·Phase 2·NCT04398368·25 enrolled

Liver Cancer2 trials

Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006010·25 enrolled

Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00941967·78 enrolled

Cancer of Unknown Primary2 trials

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00066781·31 enrolled

Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00357630·52 enrolled

Uterine Leiomyosarcoma2 trials

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Completed·GGynecologic Oncology Group·Phase 2·NCT00101127

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Terminated·GGynecologic Oncology Group·Phase 3·NCT01533207·38 enrolled

Patients With Solid Tumors2 trials

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Completed·PProacta, Incorporated·Phase 1·NCT00459836·42 enrolled

Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00072436·58 enrolled

Chemotherapy2 trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005958

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Completed·GGynecologic Oncology Group·Phase 2·NCT00031629·51 enrolled

Gallbladder Cancer2 trials

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06591650·33 enrolled

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00059865·68 enrolled

Locally Advanced2 trials

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00658593·19 enrolled

Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00079079·34 enrolled

Peritoneal Cancer2 trials

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Active, not recruiting·—·Phase 1·NCT01970722·40 enrolled

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Terminated·MMayo Clinic·Phase 2·NCT02364713·17 enrolled

Primary Peritoneal Cancer2 trials

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003358·24 enrolled

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003378·45 enrolled

Refractory Solid Tumors2 trials

Gemcitabine in Treating Children With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005577·30 enrolled

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting·NNorthwestern University·Phase 2·NCT05733000·94 enrolled

Advanced Solid Tumors1 trial

Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00054288

Advanced or Metastatic Solid Tumors1 trial

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT02495896·61 enrolled

Metastatic Colorectal Cancer1 trial

Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Unknown status·SStony Brook University·Phase 1/2·NCT00003001·63 enrolled

Solid Tumors1 trial

Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors

Completed·NNorthwestern University·Phase 1·NCT00004090

Metastatic Prostate Cancer1 trial

Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed·—·Phase 2·NCT00276549·35 enrolled

Squamous Cell Cancer of the Head and Neck1 trial

Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck

Unknown status·HHope Cancer Institute, Inc.·Phase 1/2·NCT00003182·40 enrolled

Cholangiocarcinoma1 trial

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00033540·57 enrolled

Metastatic Urothelial Cancer1 trial

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02567409·87 enrolled

Multiple Myeloma1 trial

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Endometrial Cancer1 trial

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00820898·24 enrolled

Head and Neck Cancer1 trial

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

Completed·MMedical University of South Carolina·Phase 2·NCT00509665·18 enrolled

Recurrent Head and Neck Cancer1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 1·NCT00004097

Nausea and vomiting1 trial

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT01534637·22 enrolled

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Recurrent Cancer1 trial

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Terminated·GGynecologic Oncology Group·Phase 2·NCT00006482

Chronic Lymphocytic Leukemia1 trial

Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005829·22 enrolled

Mesothelioma1 trial

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Completed·SSwiss Cancer Institute·Phase 2·NCT00030745·61 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn·EEmory University·Phase 2·NCT05514912

Gemcitabine1 trial

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00093496·29 enrolled

Unresectable Solid Tumor1 trial

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00078962·40 enrolled

Cervical Cancer1 trial

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00068549·13 enrolled

Metastatic Colon Cancer1 trial

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

Terminated·UUniversity of Miami·Phase 2·NCT00276861·10 enrolled

Intestinal Cancer1 trial

Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer

Completed·—·Phase 1·NCT00544193·16 enrolled

Lymphoid Malignancies1 trial

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00072514·55 enrolled

Nasopharyngeal Cancer1 trial

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00690872·35 enrolled

Small Cell Lung Cancer1 trial

S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00030433·85 enrolled

Breast1 trial

Chemotherapeutic Agents in Brain/Breast

Completed·—··NCT00795678·10 enrolled

Uterine Cancer1 trial

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00114218·28 enrolled

Chondrosarcoma1 trial

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00073983·54 enrolled

Stereotactic Body Radiation Therapy1 trial

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Completed·—·Phase 1·NCT01652794·12 enrolled

Recurrent or Refractory Solid Tumors1 trial

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·NNYU Langone Health·Phase 1·NCT00003144·44 enrolled

Germ Cell Tumor1 trial

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003518·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 478 trial records for gemcitabine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

Gemzar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q1 2028

Q1 2030

Trials by Indication[1]

Pancreatic Cancer44 trials

Non-Small Cell Lung Cancer30 trials

Lymphoma14 trials

Breast Cancer13 trials

Patients With Advanced Solid Tumors9 trials

Bladder Cancer8 trials

Kidney Cancer6 trials

Advanced Cancer4 trials

Cancer of the Pancreas4 trials

Radiation Therapy3 trials

Biliary Tract Cancer3 trials

Metastatic Solid Tumors3 trials

Fallopian Tube Cancer3 trials

Colorectal Cancer2 trials

Urothelial Cancer2 trials

Liver Cancer2 trials

Cancer of Unknown Primary2 trials

Uterine Leiomyosarcoma2 trials

Patients With Solid Tumors2 trials

Chemotherapy2 trials

Gallbladder Cancer2 trials

Locally Advanced2 trials

Peritoneal Cancer2 trials

Primary Peritoneal Cancer2 trials

Refractory Solid Tumors2 trials

Advanced Solid Tumors1 trial

Advanced or Metastatic Solid Tumors1 trial

Metastatic Colorectal Cancer1 trial

Solid Tumors1 trial

Metastatic Prostate Cancer1 trial

Squamous Cell Cancer of the Head and Neck1 trial

Cholangiocarcinoma1 trial

Metastatic Urothelial Cancer1 trial

Multiple Myeloma1 trial

Endometrial Cancer1 trial

Head and Neck Cancer1 trial

Recurrent Head and Neck Cancer1 trial

Nausea and vomiting1 trial

Chronic Myelogenous Leukemia1 trial

Recurrent Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Mesothelioma1 trial

Intrahepatic Cholangiocarcinoma1 trial

Gemcitabine1 trial

Unresectable Solid Tumor1 trial

Cervical Cancer1 trial

Metastatic Colon Cancer1 trial

Intestinal Cancer1 trial

Lymphoid Malignancies1 trial

Nasopharyngeal Cancer1 trial

Small Cell Lung Cancer1 trial

Breast1 trial

Uterine Cancer1 trial

Chondrosarcoma1 trial

Stereotactic Body Radiation Therapy1 trial

Recurrent or Refractory Solid Tumors1 trial

Germ Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News